{"id":"gonadorelin","rwe":[{"pmid":"41864162","year":"2026","title":"A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41698585","year":"2026","title":"Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows.","finding":"","journal":"Journal of dairy science","studyType":"Clinical Study"},{"pmid":"41579561","year":"2026","title":"Stress-related cortisol and progesterone concentrations influence the success of ovulation induction in estrous cats.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41538921","year":"2026","title":"Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41384863","year":"2025","title":"Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls.","finding":"","journal":"Endocrine connections","studyType":"Clinical Study"}],"tags":[{"label":"gonadorelin","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"H01CA01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Amenorrhea","category":"indication"},{"label":"Diagnostic Test for Gonadotropin Deficiency","category":"indication"},{"label":"Approved 1980s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":160.05,"date":"","count":42,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=160)"},{"llr":110.839,"date":"","count":60,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=111)"},{"llr":110.307,"date":"","count":21,"signal":"Ovarian hyperstimulation syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=110)"},{"llr":70.876,"date":"","count":35,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=71)"},{"llr":56.221,"date":"","count":10,"signal":"Recalled product administered","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=56)"},{"llr":46.04,"date":"","count":13,"signal":"Metastases to lymph nodes","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=46)"},{"llr":43.113,"date":"","count":9,"signal":"Carcinoembryonic antigen increased","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=43)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GONADORELIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:28:06.308301+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:28:12.235691+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GONADORELIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:28:12.551921+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:28:13.625495+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200511/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:28:13.276577+00:00"}},"allNames":"fertagyl","offLabel":[],"synonyms":["gonadorelin","Luteinizing hormone-releasing factor (swine)","hypocrine","fertagyl","gonadorelin hydrochloride","gonadorelin acetate","gonadorelin HCl","gonadorelin diacetate tetrahydrate"],"timeline":[{"date":"1982-09-30","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Fertagyl (Gonadorelin) is a gonadorelin, a small molecule that targets the gonadotropin-releasing hormone receptor. It was originally developed and is currently owned by a pharmaceutical company. Fertagyl is FDA-approved for treating amenorrhea and as a diagnostic test for gonadotropin deficiency, with an approval date of 1982. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As an off-patent drug, its commercial status is uncertain.","approvals":[{"date":"1982-09-30","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Fertagyl","ecosystem":[{"indication":"Amenorrhea","otherDrugs":[],"globalPrevalence":null},{"indication":"Diagnostic Test for Gonadotropin Deficiency","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"First-in-class","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"}],"modality":"Peptide","drugClass":"gonadorelin","explanation":"","oneSentence":"","technicalDetail":"Fertagyl acts as an agonist at the gonadotropin-releasing hormone receptor, mimicking the action of the natural hormone and stimulating the release of luteinizing hormone and follicle-stimulating hormone from the anterior pituitary gland."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-09-30, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2958","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GONADORELIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GONADORELIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:47:51.734275","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:28:14.900690+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"nafarelin","drugSlug":"nafarelin","fdaApproval":"1990-02-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"gonadorelin","indications":{"approved":[{"name":"Amenorrhea","source":"DrugCentral","snomedId":14302001,"regulator":"FDA"},{"name":"Diagnostic Test for Gonadotropin Deficiency","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"nafarelin","brandName":"nafarelin","genericName":"nafarelin","approvalYear":"1990","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04705038","phase":"NA","title":"Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-12-18","conditions":["Prostate Cancer"],"enrollment":101,"completionDate":"2025-04-30"},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":["Prostate Cancer"],"enrollment":102,"completionDate":"2027-02-14"},{"nctId":"NCT02858336","phase":"NA","title":"CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)","status":"COMPLETED","sponsor":"National Institute of Environmental Health Sciences (NIEHS)","startDate":"2017-01-12","conditions":["Hormones"],"enrollment":38,"completionDate":"2019-06-29"},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":["Breast Neoplasms"],"enrollment":600,"completionDate":"2029-12"},{"nctId":"NCT04325828","phase":"PHASE2","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-04-07","conditions":["Salivary Gland Neoplasms"],"enrollment":31,"completionDate":"2027-12-31"},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":["Prostate Cancer Metastatic Disease"],"enrollment":192,"completionDate":"2028-12-31"},{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":["Systemic Lupus Erythematosus (Sle)","Primary Ovarian Insufficiency (Poi)"],"enrollment":100,"completionDate":"2027-05-31"},{"nctId":"NCT07426094","phase":"PHASE2,PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":["Prostate Cancer","Brachytherapy","Stereotactic Body Radiation Therapy (SBRT)","Dose Escalation: Solid Tumors","Regionally Advanced Prostate Cancer"],"enrollment":1600,"completionDate":"2035-12-01"},{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":["Transgender"],"enrollment":70,"completionDate":"2025-10-31"},{"nctId":"NCT07426055","phase":"PHASE2,PHASE3","title":"PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":["Prostate Cancer (Adenocarcinoma)","Prostate Brachytherapy","Stereotactic Body Radiation Therapy (SBRT)","Dose Escalation: Solid Tumors","Localized Prostate Cancer"],"enrollment":1200,"completionDate":"2035-12"},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":["Prostate Carcinoma"],"enrollment":27,"completionDate":"2028-05-31"},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":["Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer"],"enrollment":303,"completionDate":"2027-08-25"},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":["Metastatic Hormone-Sensitive Prostate Cancer"],"enrollment":1251,"completionDate":"2026-03-27"},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":["Prostate Cancer"],"enrollment":1052,"completionDate":"2027-12-31"},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":["Adult Ovarian Granulosa Cell Tumor"],"enrollment":37,"completionDate":"2027-05-31"},{"nctId":"NCT06282588","phase":"PHASE2,PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":["Prostate Cancer"],"enrollment":493,"completionDate":"2030-12-31"},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":["Prostatic Neoplasms"],"enrollment":2517,"completionDate":"2028-10-13"},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":["Prostate Cancer","High-risk Prostate Cancer"],"enrollment":40,"completionDate":"2031-05-02"},{"nctId":"NCT07483658","phase":"NA","title":"Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.","status":"NOT_YET_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2026-02","conditions":["Reccurent/Metastatic Solid Tumor Disease","Prostate Cancer (Post Prostatectomy)","Prostate Cancer","Prostatic Neoplasms","Neoplasm Recurrence, Local","Biochemical Recurrence of Malignant Neoplasm of Prostate"],"enrollment":434,"completionDate":"2036-02"},{"nctId":"NCT02531516","phase":"PHASE3","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-19","conditions":["Prostatic Neoplasms"],"enrollment":1503,"completionDate":"2028-12-29"},{"nctId":"NCT02871167","phase":"NA","title":"Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2016-12","conditions":["Breast Cancer"],"enrollment":140,"completionDate":"2034-11"},{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":["Infertility"],"enrollment":333,"completionDate":"2029-06-30"},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":12,"completionDate":"2027-09"},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":["Biochemically Recurrent Prostate Cancer"],"enrollment":985,"completionDate":"2030-03-29"},{"nctId":"NCT04037254","phase":"PHASE1,PHASE2","title":"Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2019-10-08","conditions":["Prostate Adenocarcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":22,"completionDate":"2025-12-23"},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":["Prostatic Neoplasms"],"enrollment":75,"completionDate":"2026-06-05"},{"nctId":"NCT07319429","phase":"PHASE2,PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":["Endometrial Cancer","Fertility"],"enrollment":260,"completionDate":"2029-12-31"},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":["Prostatic Neoplasms"],"enrollment":693,"completionDate":"2029-08-27"},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":["Advanced Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","ESR1 Gene Mutation"],"enrollment":240,"completionDate":"2028-04"},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":["Early Breast Cancer"],"enrollment":200,"completionDate":"2033-02-28"},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma in the Soft Tissue","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":223,"completionDate":"2026-04-01"},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":["Castration-Sensitive Prostate Adenocarcinoma","Metastatic Castration-Sensitive Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":60,"completionDate":"2029-06-01"},{"nctId":"NCT07457164","phase":"PHASE2","title":"A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Antev Ltd.","startDate":"2026-07","conditions":["Advanced Prostate Cancer","GnRH Antagonist"],"enrollment":40,"completionDate":"2027-12"},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2034-06-01"},{"nctId":"NCT07310420","phase":"PHASE1","title":"A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"TerSera Therapeutics LLC","startDate":"2026-04-29","conditions":["Advanced Breast Cancer"],"enrollment":88,"completionDate":"2027-03-30"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":["Ovarian Cancer"],"enrollment":176,"completionDate":"2028-05-30"},{"nctId":"NCT07460752","phase":"PHASE2","title":"Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-24","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Locally Advanced Hormone Receptor-Positive Breast Carcinoma"],"enrollment":98,"completionDate":"2029-09-26"},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"],"enrollment":1050,"completionDate":"2029-02-12"},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":["Prostate Adenocarcinoma","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8"],"enrollment":70,"completionDate":"2027-12-31"},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":["Prostate Cancer","Advanced Prostate Cancer","Hormone Sensitive Prostate Cancer"],"enrollment":33,"completionDate":"2028-11-30"},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":["Prostate Cancer"],"enrollment":1538,"completionDate":"2025-09-04"},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":["Prostate Cancer"],"enrollment":239,"completionDate":"2025-09-04"},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":["Prostate Cancer","Castrate Sensitive Prostate Cancer","Oligometastatic Disease"],"enrollment":21,"completionDate":"2026-05"},{"nctId":"NCT05901467","phase":"PHASE1","title":"Recall by Genotype: Neuropeptide Stimulation","status":"TERMINATED","sponsor":"Stephanie B. Seminara, MD","startDate":"2023-10-20","conditions":["Reproductive Disorder"],"enrollment":16,"completionDate":"2024-05-29"},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":["Prostate Cancer","Localized Prostate Carcinoma"],"enrollment":50,"completionDate":"2030-10"},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":["Prostatic Neoplasms"],"enrollment":10,"completionDate":"2026-01-21"},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":["Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":90,"completionDate":"2028-04-01"},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":["Metastatic Breast Cancer"],"enrollment":230,"completionDate":"2032-12-28"},{"nctId":"NCT07444983","phase":"NA","title":"Rezvilutamide for High-Risk Prostate Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-11","conditions":["Prostate Cancer (Adenocarcinoma)"],"enrollment":33,"completionDate":"2029-07-11"},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":["Breast Cancer"],"enrollment":3960,"completionDate":"2034-07"},{"nctId":"NCT07015268","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Patients With Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2025-06-09","conditions":["Endometriosis"],"enrollment":288,"completionDate":"2027-11"},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":["Early Breast Cancer"],"enrollment":1400,"completionDate":"2030-09-20"},{"nctId":"NCT02653092","phase":"NA","title":"Reprometabolic Syndrome Mediates Subfertility in Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2016-06","conditions":["Obesity","Infertility","Hypogonadotropic Hypogonadotropism","Hyperinsulinemia"],"enrollment":84,"completionDate":"2026-12-11"},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":["Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":804,"completionDate":"2032-12-31"},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":["Menopausal Osteoporosis","Bone Markers"],"enrollment":192,"completionDate":"2028-05"},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":["Androgen Deprivation Therapy","Prostate Cancer","Hypertension","Autonomic Dysfunction","Renal Disease"],"enrollment":10,"completionDate":"2025-07-16"},{"nctId":"NCT06395753","phase":"PHASE2","title":"A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2024-05-23","conditions":["Prostate Cancer"],"enrollment":66,"completionDate":"2027-01"},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":["Metastatic Prostate Cancer","Non-metastatic Prostate Cancer","Prostate Cancer"],"enrollment":9,"completionDate":"2026-06-01"},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Unresectable HER2-Negative Breast Carcinoma","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":60,"completionDate":"2028-06-01"},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":["Prostatic Neoplasms"],"enrollment":669,"completionDate":"2026-01-23"},{"nctId":"NCT07097259","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-07-21","conditions":["Hypogonadism"],"enrollment":55,"completionDate":"2025-12-23"},{"nctId":"NCT06513962","phase":"PHASE3","title":"Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-27","conditions":["Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm"],"enrollment":60,"completionDate":"2029-10-30"},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":["Recurrent Prostate Carcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":72,"completionDate":"2029-07-01"},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":["Castration-Resistant Prostatic Cancer","Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer","Hormone-Refractory Prostate Cancer"],"enrollment":100,"completionDate":"2029-08"},{"nctId":"NCT05896566","phase":"PHASE2","title":"A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2024-01-23","conditions":["Breast Cancer"],"enrollment":231,"completionDate":"2025-09-18"},{"nctId":"NCT03388619","phase":"PHASE1","title":"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-17","conditions":["Cancer Of Prostate","Prostate Neoplasms","Prostate Cancer","Neoplasms of Prostate","Prostatic Cancer"],"enrollment":30,"completionDate":"2025-12-04"},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":["Early Breast Cancer"],"enrollment":4170,"completionDate":"2035-01-01"},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":["Prostate Adenocarcinoma","Recurrent Prostate Carcinoma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT04546009","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-09","conditions":["Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer"],"enrollment":992,"completionDate":"2028-03-25"},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":14,"completionDate":"2027-12-15"},{"nctId":"NCT04648969","phase":"PHASE2","title":"Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism","status":"COMPLETED","sponsor":"Stephanie B. Seminara, MD","startDate":"2019-05-03","conditions":["Hypogonadotropic Hypogonadism"],"enrollment":18,"completionDate":"2025-08-31"},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":["Triple Negative Breast Cancer"],"enrollment":85,"completionDate":"2032-06"},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":["Prostate Cancer Metastatic","Radiation Therapy","Positron-Emission Tomography"],"enrollment":118,"completionDate":"2033-12"},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","HER2-positive Breast Cancer","Breast Cancer"],"enrollment":74,"completionDate":"2036-07-01"},{"nctId":"NCT07158021","phase":"PHASE2","title":"Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-01-22","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma"],"enrollment":75,"completionDate":"2028-01-01"},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":["Breast Cancer"],"enrollment":181,"completionDate":"2026-07-31"},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":["Biochemically Recurrent Prostate Carcinoma","Localized Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8"],"enrollment":94,"completionDate":"2026-10-30"},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":["Breast Cancer"],"enrollment":200,"completionDate":"2030-06"},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":["Breast Cancer","Oligometastasis","Metastatic Breast Cancer"],"enrollment":340,"completionDate":"2032-10-31"},{"nctId":"NCT07394530","phase":"NA","title":"Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS","status":"RECRUITING","sponsor":"Hanoi General Hospital (Vietnam)","startDate":"2026-01-20","conditions":["Polycystic Ovary Syndrome (PCOS)","Female Infertility"],"enrollment":400,"completionDate":"2028-06-30"},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":["Prostate Cancer"],"enrollment":144,"completionDate":"2026-09"},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":["Breast Cancer"],"enrollment":1939,"completionDate":"2030-01"},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":223,"completionDate":"2026-06-05"},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":["Breast Cancer"],"enrollment":2672,"completionDate":"2024-10-23"},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":["Estrogen Receptor Positive Breast Cancer","Progesterone Receptor Positive Tumor","Recurrent Breast Carcinoma","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer"],"enrollment":3066,"completionDate":"2024-11-06"},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":["Metastatic Hormone Sensitive Prostate Cancer"],"enrollment":180,"completionDate":"2028-12-31"},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":["Prostate CA","Prostate Cancer (Adenocarcinoma)","Prostate Cancer Surgery"],"enrollment":30,"completionDate":"2026-06"},{"nctId":"NCT03902951","phase":"PHASE2","title":"Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-03-17","conditions":["Metastatic Prostate Adenocarcinoma","Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation","Recurrent Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":28,"completionDate":"2028-01-01"},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":61,"completionDate":"2027-09"},{"nctId":"NCT06523530","phase":"PHASE4","title":"Effect of a GnRH Analog on Hepatic Steatosis","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-11-26","conditions":["Metabolic Dysfunction-Associated Steatotic Liver Disease","Nonalcoholic Fatty Liver","Endometriosis"],"enrollment":62,"completionDate":"2027-10"},{"nctId":"NCT05326087","phase":"PHASE3","title":"Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","status":"NOT_YET_RECRUITING","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2026-06-01","conditions":["Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","Polycystic Ovarian Syndrome","GnRH Antagonist"],"enrollment":204,"completionDate":"2028-12-01"},{"nctId":"NCT05161195","phase":"PHASE4","title":"Roll-over Study to Allow Continued Access to Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-07","conditions":["Metastatic Breast Cancer"],"enrollment":134,"completionDate":"2030-08-14"},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":["Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer"],"enrollment":373,"completionDate":"2026-10-15"},{"nctId":"NCT05568550","phase":"PHASE2","title":"Pembro With Radiation With or Without Olaparib","status":"RECRUITING","sponsor":"Zin W Myint","startDate":"2023-07-27","conditions":["Prostate Cancer"],"enrollment":64,"completionDate":"2029-07-02"},{"nctId":"NCT03553602","phase":"PHASE1,PHASE2","title":"HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer","status":"TERMINATED","sponsor":"Loyola University","startDate":"2017-12-20","conditions":["Prostate Cancer - Recurrent"],"enrollment":3,"completionDate":"2024-07-26"},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":["Metastatic Castration Sensitive Prostate Cancer (mCSPC)","Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":1083,"completionDate":"2024-04-10"},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":["Prostate Cancer"],"enrollment":392,"completionDate":"2031-04-16"},{"nctId":"NCT04989946","phase":"PHASE1,PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2028-12"},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":70,"completionDate":"2027-08-23"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147858","MMSL":"4796","NDDF":"002108","UNII":"9O7312W37G","VUID":"4019767","CHEBI":"CHEBI:5520","VANDF":"4018487","INN_ID":"3627","RXNORM":"1298838","UMLSCUI":"C0023610","chemblId":"CHEMBL1200511","ChEMBL_ID":"CHEMBL1007","KEGG_DRUG":"D00988","DRUGBANK_ID":"DB00644","PUBCHEM_CID":"638793","SNOMEDCT_US":"325995009","SECONDARY_CAS_RN":"51952-41-1","MESH_DESCRIPTOR_UI":"D007987"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":292,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01CA01","allCodes":["H01CA01","V04CM01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 17","pmid":"41864162","title":"A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle.","journal":"Theriogenology"},{"date":"2026 Feb 14","pmid":"41698585","title":"Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows.","journal":"Journal of dairy science"},{"date":"2026 Apr 15","pmid":"41579561","title":"Stress-related cortisol and progesterone concentrations influence the success of ovulation induction in estrous cats.","journal":"Theriogenology"},{"date":"2026 Apr 1","pmid":"41538921","title":"Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.","journal":"Theriogenology"},{"date":"2025 Dec 1","pmid":"41384863","title":"Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls.","journal":"Endocrine connections"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-09-30T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:28:14.900690+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}